Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC
(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer or PROC in an oral presentation at the Society of Gynecologic Oncology (SGO) 2025 A
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
